Over the fence sounds safe enough - fingers crossed for you, Stilly. It's in enclosed places that the nasty little bugs can do their thing most efficiently.
Pfizer has new drugs that sound better than remdesevir, apparently. From an Irish Times piece last month:

Pfizer’s preliminary results from its clinical trial of the drug combination Lopinavir/ ritonavir showed a reduction of between 85 and 89 per cent in the combined rate of hospitalisation and death among those who got the drug, compared to those who got a placebo pill. For patients who started taking the drug within three days of the onset of symptoms, the hospitalisation rate was 89 per cent lower.
The reduction in hospitalisation was slightly less (85 per cent) among those who took the pills a day or two later (but within five days of symptoms developing). Lopinavir is a protease inhibitor and is from the same family of drugs used to treat HIV/AIDS and hepatitis C. It works by blocking an enzyme that the virus needs to multiply. The new medication is taken with an older protease inhibitor called ritonavir, which boosts the level of lopinavir in the body.
Molnupiravir, MSD’s new medication, reduced the rate of hospitalisation by 50 per cent among recipients, compared to those who got a placebo pill. That was among patients who started taking the medication within five days of symptoms beginning.
The new antiviral medication was approved for use by regulators in the UK earlier this month, who said molnupiravir (Lagevrio) is safe and effective at reducing the risk of hospitalisation and death in people with mild to moderate Covid-19 symptoms, who have at least one risk factor for developing serious illness.